News & Events

In this section

Published originally by Logos Technologies prior to Instem ownership, included here for information purposes

SNBL chooses ALPHADAS®, Logos Technologies’ Early Phase EDC System

8th April 2013

Logos Technologies is delighted to announce today that SNBL, CPC Inc (SNBL) has entered into an agreement with Logos Technologies’ for its’ market leading, early phase, e-source data capture system and site automation software suite which gives clinical research sites unsurpassedtools to accelerate and streamline their clinical trial operations and service. ALPHADAS is to be implemented in SNBL’s 96 bed Clinical Pharmacology Center in Baltimore, USA.

Giles Wilson, CEO of Logos Technologies said, “We are delighted to be working with SNBL. Their decision to choose ALPHADAS over our competitors is a clear demonstration of the in depth functionality, innovation and performance that ALPHADAS delivers, as demonstrated by the number of sites Logos has in full regulatory production.”

Giles Continued “Critical to their decision was how far ahead of the curve Logos are technologically. ALPHADAS is a clinical reality, not a developers promise and our use of online solutions really has gone one step beyond simple browser based technology, which by itself is limited in utility for early phase trials. We look forward to working with the SNBL team so they can benefit immediately from the compelling ROI that ALPHADAS provides.”

Takeshi Yamakawa, Chief Executive Officer at SNBL said, “Our team is very excited to start the process of implementing the ALPHADAS EDC system in our clinical pharmacology unit in Baltimore.  Through our assessment of potential EDC solutions, it became very clear that Logos Technologies completely understands the needs of clinical research sites that conduct complex early phase inpatient clinical pharmacology trials”.

Mark Cusack, VP Global Business Development of Logos Technologies adds, “SNBL are well experienced in early phase data capture systems, so their endorsement of ALPHADAS is especially significant. Their current system is being retired by it’s vendor. What was critical was the provision of a straightforward, symbiotic upgrade path with the market proven ALPHADAS, delivered by a team with unsurpassed industry experience. This was key in winning all at SNBL over to ALPHADAS, from the clinic floor to the executive. We are delighted to welcome them into the ever growing ALPHADAS fraternity.”

SNBL CPC, Inc. is a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, LTD, the largest CRO in Japan with over a thousand employees. The second of two U.S.-based subsidiaries, SNBL CPC, Inc. focuses on Phase I/IIa complex clinical pharmacology research with a mission to freeing patients from suffering, by supporting drug development and improving medical technology.

ALPHADAS, is an e-Source, pro-active EDC automation system designed specifically for early phase clinical trials which has achieved great success.  It is a market proven solution that offers a depth of functionality other systems cannot provide. The dedicated team behind ALPHADAS are Experts in Early Phase EDC and provide an unrivalled level of service, experience and expertise to its clients. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it theSystem of Choice’ for early phase EDC.

About SNBL (CPC)

SNBL CPC is a 96 bed full service Clinical Pharmacology Research facility based in Baltimore, Maryland. Our team is focused on performing high complexity early phase clinical research programs. We conduct clinical trials for multiple segments of clients, including, pharmaceutical, biotech, academic, and government. SNBL’s focus is on First In-Human, Dose Escalation, SAD, MAD, Food Effect, Novel Delivery, Adaptive design, and Infectious Disease challenge studies sets us apart from the vast majority of Early Phase inpatient clinical research facilities. SNBL CPC is pleased to offer our new, state of the art clinical safety laboratory that performs all of the standard safety analyses and moderate to high complexity test procedures.

Press Contact:

Angela King